Roche's Genentech announced Gazyva data that met primary, secondary endpoints
Genentech, a member of the Roche Group (RHHBY), announced data from the Phase II NOBILITY study, investigating the safety and efficacy of Gazyva for adults with proliferative lupus nephritis. The study met the primary endpoint with Gazyva, in combination with standard of care, demonstrating superiority compared to placebo plus standard of care. Gazyva additionally met key secondary efficacy endpoints showing improved overall renal response and serologic markers of disease activity as compared to placebo. No new safety signals were observed with Gazyva in the study at the time of this analysis. Through week 76, serious adverse events and serious infections were not increased with Gazyva. These data will be presented at the 2019 American College of Rheumatology Annual Meeting in Atlanta, Georgia, on November 10.